...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
Reply New Message
Back To Forum List View
Icon president Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
3
BearDownAZ
Jun 27, 2019 08:36AM
Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
4
Nextblockbuster
Jun 27, 2019 10:43AM
Icon president Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
7
BearDownAZ
Sep 02, 2019 10:14AM
Icon president Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
6
BearDownAZ
Oct 18, 2019 12:56PM

Study site locations and investigators now up to 10 according to the BIO Investor Forum slide deck. Includes some from Belgium and Spain in addition to US sites. Moving along nicely!

BDAZ

5 Recommendations
Icon president Re: Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
7
Toinv
Oct 25, 2019 11:07AM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply